A wealth of scientific and clinical evidence during the past few years has lent credence to the idea that key components of the host immune effector mechanisms can be targeted to boost current tuberculosis (TB) treatment and control patient relapse. These host-directed strategies not only accelerate the clearance of pathogens but also have the ability to limit overt inflammation 
INTRODUCTION
TB caused by Mtb is an old infectious disease, 1 yet it remains a major cause of death worldwide, with an estimated 10 million new cases and 1.5 million deaths every year (World Health Organization, 2016), despite the discovery of effective and affordable chemotherapy > 50 y ago. Although the current treatment of drug-susceptible TB is effective, the treatment duration is exhaustively long (6-9 mo), and the therapeutic agents can result in substantial toxicity. Furthermore, the emergence of drug-resistant strains and the sudden increase in the incidence of HIV and diabetes in the population, has made TB, a global epidemic, harder to control. 2, 3 Therefore, new treatment approaches and regimens based on novel concepts are urgently Abbreviations: AMPK, AMP-activated protein kinase; Atg, autophagy related; CD, cluster of differentiation; DCs, dendritic cells; FAO, fatty acid oxidation; HDT, host-directed therapy; HIF-1 , hypoxia-inducible factor-1 ; LKB1, liver kinase B1; Mtb, Mycobacterium tuberculosis; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; NAM, nicotinamide; to the prevention and/or resolution of infectious diseases. These switches in nutrient intake, use, and storage are controlled by carefully tuned regulatory and evolutionarily conserved programs involving classic metabolic sensors such as mTOR, 7 AMPK, 8 and sirtuins. 9 The crosstalk between these energy sensors also regulates metabolic stress response pathways, such as autophagy, which have been shown to modulate innate and adaptive immune responses in different clinical settings, such as cancer, autoimmune diseases, and infections. [10] [11] [12] [13] [14] [15] [16] [17] [18] Hence, it is evident that the functional connections between host immunity and metabolism can be targeted to reprogram host immune defenses. Many comprehensive and up-to-date reviews on mTOR, immunity, and infections are available (see references 11, 19, 20) . In the present report, we have focused on recent advances in the mechanisms that ascertain the role of AMPK and sirtuins, mainly sirtuin 1 (silent mating type information regulation 2 homolog 1), in the immune response during inflammation and infection and consider approaches by which these metabolic sensors can be manipulated to potentiate antibacterial and, more specifically, anti-Mtb effects.
AMPK: A MASTER REGULATOR MAINTAINING CELLULAR ENERGY HOMEOSTASIS, GROWTH, AND METABOLISM
Central to the control of energy homeostasis in mammals is AMPK, a phylogenetically conserved serine/threonine protein kinase, activated by various types of metabolic stresses. 12, 21, 22 AMPK switches on catabolic pathways such as glucose uptake, glycolysis, fatty acid uptake, and FAO, which lead to ATP generation and switches off anabolic pathways such as fatty acid, glycogen, and protein synthesis, which consume ATP. 21 A decrease in energy level, especially intracellular ATP, and a simultaneous increase in AMP or ADP results in energy stress and activates AMPK. In eukaryotes, AMPK, a heterotrimeric complex, consists of 1 catalytic subunit, , and 2 regulatory subunits, and . 23 When the AMP/ATP or ADP/ATP ratio increases, AMP or ADP bind to the -subunit of AMPK. Subsequently, the AMPK kinase LKB1 induces the phosphorylation of Thr172 in the activation loop of AMPK. Another approach to phosphorylate Thr172 is by calcium flux via Ca 2+ -calmodulin-dependent protein kinase kinase/Ca 2+ -calmodulin-dependent protein kinase kinase-. Alternatively, TAK1, a MAPK kinase kinase family member (MAP3K7), also activates AMPK via phosphorylation. 24 AMPK is a key reprogrammer of cell growth, lipid and glucose metabolism, and cell polarity. 23, 25 AMPK regulates cell growth by suppressing mTORC1, either by phosphorylating TSC2 on Ser1387 or by phosphorylating raptor on two serines. 23 As an upstream kinase, AMPK phosphorylates the metabolic enzymes acetyl-CoA carboxylase 1, sterol regulatory element-binding protein-1c, and 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, and thus suppresses, respectively, fatty acid and sterol synthesis by downregulating the expression of key enzymes. 23, 24 AMPK not only suppresses lipid anabolism but also promotes lipid catabolism by phosphorylating acetyl-CoA carboxylase 2 in the mitochondria, which activates carnitine palmitoyltransferase-1. Carnitine palmitoyltransferase-1, in turn, inhibits the production of malonyl-CoA and leads to FAO in mitochondria. AMPK stimulates glucose uptake by phosphorylating Rag-GTPase-activating protein TBC1D1, which leads to the fusion of Glut4 vesicle across the plasma membrane. After glucose is in the cell, it is metabolized in glycolysis or glycogen synthesis, both regulated by AMPK. In monocytes/macrophages, AMPK promotes glycolysis by phosphorylating 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase and prevents glycogen synthesis by inhibiting phosphorylation of glucogen synthase. 26 to anti-inflammatory M2 macrophages 32 and also attenuates TLR agonist-mediated aerobic glycolysis, known as the Warburg effect, required for DC maturation. 37 Novel insights have been reported regarding the inflammation (mainly LPS)-mediated metabolic changes in macrophages and DCs. 38 The interaction of bacterial species, such as Listeria monocytogenes, 15 Mycobacterium bovis BCG, 39 and Salmonella typhimurium, 40 with the host also leads to a variety of AMPKmediated metabolic changes, which, most often, converge directly or indirectly on mTORC1. This fine-tuned balance between AMPK and mTOR-mediated control of cellular metabolism is also important for Mtb virulence [41] [42] [43] and Salmonella enterica infection. 44 
YIN AND YANG OF AMPK WITH INFLAMMATION AND INFECTION

SIRTUINS-AN EVOLUTIONARY CONSERVED METABOLIC MODULATOR
Sirtuins are a highly conserved family of proteins that have diverse functions in a broad range of physiologic settings. 45 They were initially identified as orthologs of the yeast Sir2 protein. In Saccharomyces cervisae, the Sir2 gene was found to be a regulator of transcriptional silencing of mating-type loci, telomeres, and ribosomal DNA and is able to extend the lifespan of yeast. 46 Thereafter, because of the surge in interest in understanding this longevity-promoting phenotype, similar homologs have since been described in mammals, plants, and bacteria. 47 In mammals, the sirtuin family comprises 7 proteins (SIRT1 to SIRT7), distinguished by their subcellular location and deacetylation targets. Among all the sirtuins, SIRT1 has been the best characterized and bears the closest homology to protein encoded by the yeast gene. 48 Like Sir2, SIRT1 belongs to the class III histone deacetylase family of enzymes and is highly dependent on NAD + for its deacetylase activity. SIRT1 resides mainly in the nucleus but can shuttle to the cytosol in which are several of its targets. 49 The activity and expression of SIRT1 are tightly regulated at many levels, from the molecular level, such as substrate availability, to the gene specific regulatory level, such as activation by transcription factors, post-translation modifications, protein-protein interactions, and regulation by microRNAs. SIRT1 can also create many feed-forward loops by influencing various transcription factors to fine tune its own expression and activity, illustrating the intrinsic nature of SIRT1 control and how it is driven by multiple regulatory loops (for a full review, see Cantó et al. 50 ). The requirement for NAD + as a cosubstrate for SIRT1 activity suggests that SIRT1 is closely regulated by the availability of NAD + , important for many key metabolic processes.
In general, NAD + levels increase in mammalian tissues in response to energy/nutrient stresses such as exercise, 51 fasting, 8, 52 and calorie restriction. 53 Accordingly, SIRT1 activity is enhanced by all these conditions. SIRT1 activity can also be controlled by other NAD + -derived metabolites and NAD + -consuming proteins such as poly-ADP ribose polymerase and CD38 (ADP-ribose cyclase). CD38 hydrolyses NAD + into NAM and cyclic ADP-ribose, a second messenger involved in cellular Ca 2+ mobilization and subsequent intracellular signaling, which could lead to immune cell activation and proliferation. 54 Therefore, it has been proposed that CD38 is able to regulate the activity of SIRT1 through the degradation of NAD + and generation of NAM. 55 In line with this, CD38 deficient mice have higher levels of tissue NAD + and SIRT1 than do wild-type mice. 56 NAM, which is also a byproduct of the transferase reaction, mediated by the key NAD + biosynthetic enzyme in mammals, NAMPT, can exert a potent end product inhibition on SIRT1 activity. NAMPT is also one of the SIRT1-CLOCK-BMAL1-regulated circadian genes, in which SIRT1 and NAMPT constitute a circadian feedback loop, producing the circadian oscillation of NAD + that, in turn, drives SIRT1 activity. 57 
SIRT1 LINKS INFLAMMATION AND METABOLISM WITH GENE EXPRESSION
SIRT1 is a master regulator of chromatin remodeling and thus reprograms gene expression. 58 Ample evidence has suggested the involvement of SIRT1 in a broad range of pathophysiological conditions, such as inflammation, metabolism, and cancer by directly deacetylating proteins such as NF-B RelA/p65 and p53. 58 SIRT1 also deacetylates histone proteins such as H3K9 and H3K14, leading to the recruitment of methyltransferases, which catalyzes DNA methylation, and thus has an influence on euchromatin to heterochromatin transition. [59] [60] [61] regulates inflammation mainly by deacetylating the proinflammatory transcriptional factor NF-B RelA/p65 on K310 and histones, leading to silencing of the expression of inflammatory genes. Additionally, along with RelB, SIRT1 positively regulates I B gene expression, channeling NF-B RelA/p65 back to the cytoplasm, and thus attenuating the cytokine storm. 62 During inflammation, NAD + levels and SIRT1 transcription and/or protein levels are consistently reduced in tissues. Examples include fat deposits in obesity, brain in Alzheimer's disease, and arterial inflammation in atherosclerosis. [63] [64] [65] This reduction is accompanied by increased levels of activated (i.e., acetylated) NF-B RelA/p65 and downstream proinflammatory cytokines, which can be reversed by SIRT1 activation. Animals with altered levels of SIRT1 expression were shown to exhibit inflammatory phenotypes. 66 Myeloid cell-specific SIRT1 knockout mice develop an autoimmune condition, with a dysregulated NF-B signaling pathway 67 and are susceptible to L. monocytogenes 68 and Mtb 10 infection. In contrast, SIRT1 transgenic mice are protected against the diabetes-mediated inflammatory reactions 69 and metabolic inflammation induced by high-fat diets. 70 By modifying histones and cytoplasmic proteins, SIRT1 also integrates metabolism with the acute inflammatory process. 71 Early during the infection/inflammation process, TLR activation stimulates HIF-1 expression, leading to the transcription of genes regulating glycolysis and mitochondrial function. Recently, it has been shown that HIF-1 is crucial for IFN--dependent control of Mtb infection. 72 HIF-1 activation requires acetylation of HIF-1 at K674 by p300
and can favor sustained proinflammatory responses, which could be deleterious during chronic inflammation, indicating the dual role of HIF-1 during persistent infections such as Mtb. On interaction with HIF-1 , SIRT1 deacetylates K674 and blocks its association with p300, thus preventing HIF-1 activation. 73 During chronic inflammation, partial or complete loss of SIRT1 activity has been observed, contributing to long-lasting metabolic perturbations seen in diabetes, obesity, and chronic obstructive pulmonary disease. 58 The mechanisms underlying this resultant diminished SIRT1 activity are still unclear but could include increased microRNA-mediated degradation, reduced transcription, and/or decreased availability of NAD + .
AMPK-SIRT1 AXIS-MEDIATED REGULATION OF MITOCHONDRIAL BIOGENESIS AND AUTOPHAGY
AMPK also regulates catabolism by enhancing mitochondrial function.
In mice, AMPK has been shown to directly phosphorylate the transcriptional coactivator PGC-1 , which is a master regulator of mitochondrial biogenesis and orchestrates a variety of transcription factors to induce mitochondrial gene expression. 52 PGC-1 forms an energy sensing network, along with AMPK and SIRT1. 74 In situations of energy stress or SIRT1 activation, PGC-1 is promptly deacetylated and activated, leading to enhanced mitochondrial respiration. 52 The dual effect of AMPK and SIRT1 on mitochondrial biogenesis could be because these 2 sensors regulate each other in a positive feedback mechanism (Fig. 1A) . AMPK senses the AMP/ATP or ADP/ATP ratio in the cell on a reduction in energy stores. Activated AMPK then upregulates a myriad of genes to increase ATP generation. One of the results of AMPK activation is an increase in the NAD + /NADH ratio in the cell, which activates SIRT1. 75 In turn, SIRT1 regulates AMPK activity by deacetylating LKB1. 76 cleotide, an AMPK activator. 77 In addition to the regulation of cell growth, activation of the AMPK-SIRT1 axis can facilitate the catabolic process of autophagy by inhibiting mTOR signaling. AMPK phosphorylates the ULK1 and ULK2 complex, leading to inhibition of mTORC1. 23 SIRT1 forms molecular complexes with important components of the autophagy machinery, including Atg5, Atg7, and Atg8, by deacetylating these proteins in a NAD + -dependent manner. 78 Importance of SIRT1 in regulating autophagy is evident by accumulation of damaged organelles including mitochondria in the mouse embryonic fibroblast from SIRT1 −/− mice. 78 Forkhead box proteins, which are key regulators of lipid metabolism, stress resistance, and apoptosis, 79 also enhance autophagy in a SIRT1-mediated fashion. 80 Additionally, SIRT1 activation also upregulates expression of phosphatidylinositol-3-kinase-serine/threonine protein kinase B-mTOR signaling to enhance autophagy in an ovalbumin-induced murine asthma model. 81 Thus, AMPK-SIRT1 signaling is an important connector of immune, metabolic, and mitochondrial bioenergy networks.
TARGETING AMPK-SIRT1 AXIS FOR RESTRICTING INFECTIONS
Intracellular pathogens subvert energy sensors and manipulate host cell metabolism for their growth and persistence. 82 By modulating the AMPK-SIRT1 axis, Salmonella typhimurium targets mTOR to impair autophagy; 83 Leishmania infantum hijacks host macrophage mitochondrial metabolism; 84 and Mtb inhibits innate antimicrobicidal function by downregulating SIRT1, leading to pronounced host immunopathology. 10, 42 We recently showed that Mtb reduced intracellular NAD + expression in vitro and modulates SIRT1 activity during the course of infection. 10 This is in line with a study that showed decreased levels of NAD + in the lungs of Mtb-infected guinea pigs. 85 Additionally, Mtb depletes cellular NAD + by secreting a toxin into the host cell, 86 indicating a role of bacterial product in regulating host SIRT1 activity/expression. Reduction of SIRT1 mRNA has been observed in the blood of TB patients, which increased after 2-3 mo of anti-TB therapy, indicating an association of SIRT1 expression with TB disease activity. 10 Furthermore, SIRT1 mRNA expression in human PBMCs was reduced after treatment with Escherichia coli endotoxin. 87 In addition to bacterial pathogens, hijacking of both AMPK and SIRT1 by viruses have been documented, 84, 88 and they, in turn, are known to be important for the prevention of viral diseases. 89 Various nutritional stresses and pharmacological and natural substances can modulate AMPK activity. On glucose limitation, AMPK regulates the mitochondrial metabolism to allow effector T cells (Th1 and Th17 immune response) to clear L. monocytogenes in a pulmonary in vivo infection model. 90 Metformin and phenformin, antidiabetic biguanide class drugs, cause a moderate inhibition of complex I of the respiratory electron transport chain, which results in a decrease in intracellular ATP, leading to activation of AMPK. Metformin-mediated AMPK activation has been shown to restrict Helicobacter pylori, 91 Pseudomonas aeruginosa, 92 and Mtb 93 infections. Retrospective studies of TB patients from 3 human cohorts have also indicated that metformin could be a promising candidate for adjunctive HDT to improve the effective treatment of TB. 22, 93 Another AMPK activator, aminoimidazole-4-carboxamide ribonucleotide, has also been demonstrated to have an antimicrobial response against Mtb infection. 43 Moreover, a study of community-based infections showed that metformin reduced the risk of hospital-acquired infections. 94 The ability to modulate SIRT1 for its protective effects against aging, inflammation, and oxidative stress, observed in a wide range of animal models, has led to the discovery of many pharmacological activators for SIRT1. 95 These SIRT1-activating compounds have been used in clinical settings, although their specificity has been long debated. 50 Among these, the one receiving the most attention has been resveratrol. Resveratrol, a natural polyphenol identified 1 decade ago as a direct activator of SIRT1, is currently being studied for the treatment of several disorders involving inflammation, immunity, and degenerative diseases. 96 However, resveratrol has many mechanisms of action and has been reported to bind directly to a number of transcriptional regulators and components of the mitochondrial respiratory chain (see reference 97 for review), leading to decreased ATP expression and, consequently, greater AMPK activity 98 (Fig. 1A) . Many studies have suggested that resveratrol requires AMPK to activate SIRT1 to achieve the health benefits in in vivo settings. 99, 100 Because the oral bioavailability of resveratrol is low (<1%) owing to the rapid and extensive metabolism in the host, 101 PTS, a methoxylated derivative of resveratrol, which has a much longer half-life in the body than resveratrol, has been extensively studied. PTS has greater bioavailability and an ability to directly activate SIRT1 102 SIRT1 is dependent on NAD + -dependent lysine deacetylase activity, which is regulated by nutrient availability. Nutrient deprivation, exercise, and calorie restriction (shown in orange) increase SIRT1 activity by increasing the amount of NAD + and decreasing the abundance of NADH. AMPK activation increases NAD + by promoting FAO. High-fat diet (HFD) and glycolysis (shown in blue) can also diminish sirtuin activity due to a reduction in NAD + levels. The activation of SIRT1 leads to the deacetylation of LKB1, which activates AMPK via phosphorylation at Thr172. AMPK can also be activated by physiologic AMP/ATP or ADP/ATP elevation from energy stresses such as low nutrients or prolonged exercises (shown in purple). Likewise, both SIRT1 and AMPK activity can be stimulated allosterically by pharmacological means. The joint activation of SIRT1 and AMPK (indicated by dashed black arrows) allows for the simultaneous deacetylation and phosphorylation of the target molecules such as PGC-1 , ultimately leading to an increase in mitochondrial biogenesis and activity, increased oxidative capacity, and autophagy induction. (B) SIRT1 activity (linked to the SIRT1 expression and availability of NAD + ) dictates level of Mtb clearance, inflammation, and pathology in vivo thus, could have a more potent effect on health. 103 PTS inhibited HIV-1 replication in resting CD4 + T cells 104 and has activity against Candida 105 and methicillin-resistant Staphylococcus aureus. 106 A more recent screening test for other possible direct activators of SIRT1 has led to the identification of a second batch of compounds, one of which is SRT1720. 107 Mice administered SRT1720 showed decrease severity of pulmonary, renal, metabolic, and cardiovascular diseases. 108 SRT1720, however, has also been reported to exhibit multiple off-target activities. 109 Treatment of mice with the resveratrol and SRT1720, increased SIRT1 expression and activity, restricted Mtb growth, and reduced Mtb-mediated tissue pathology and inflammation 10 (Fig. 1B) . Similarly, Yang et al. 110 demonstrated that SIRT1 activators suppress the inflammatory response in an LPS-induced inflammation mouse model by deacetylation of p65
and inhibition of NF-B activity. The AMPK-SIRT1 axis can also be modulated by another common drug, aspirin, to improve TB treatment outcomes. [111] [112] [113] In patients with tuberculosis meningitis, aspirin resulted in a reduced frequency of stroke and reduced 3-mo mortality. 114, 115 Collectively, these findings underscore the promise of AMPK/SIRT1 activators as a novel therapeutic approach for TB.
CONCLUSIONS
Mtb has coevolved with the host immune system, acquiring a remark- 
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activated protein kinase and inducible 6-phosphofructo-2-kinase. 
